80 related articles for article (PubMed ID: 3674471)
1. Specific bradycardic agents, a new therapeutic modality for anesthesiology: hemodynamic effects of UL-FS 49 and propranolol in conscious and isoflurane-anesthetized dogs.
Riley DC; Gross GJ; Kampine JP; Warltier DC
Anesthesiology; 1987 Nov; 67(5):707-16. PubMed ID: 3674471
[TBL] [Abstract][Full Text] [Related]
2. Negative chronotropic actions of sufentanil and vecuronium in chronically instrumented dogs pretreated with propranolol and/or diltiazem.
Schmeling WT; Kampine JP; Warltier DC
Anesth Analg; 1989 Jul; 69(1):4-14. PubMed ID: 2568103
[TBL] [Abstract][Full Text] [Related]
3. Investigations into the bradycardic effects of UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on-hydrochloride) in isolated guinea pig atria.
Lillie C; Kobinger W
J Cardiovasc Pharmacol; 1986; 8(4):791-7. PubMed ID: 2427820
[TBL] [Abstract][Full Text] [Related]
4. Role of force--frequency relation during AV-block, sinus node block and beta-adrenoceptor block in conscious animals.
De Pauw M; Vilaine JP; Heyndrickx GR
Basic Res Cardiol; 2004 Sep; 99(5):360-71. PubMed ID: 15338245
[TBL] [Abstract][Full Text] [Related]
5. A bradycardic agent, UL-FS 49, increases atrial force and decreases ventricular force in isolated, perfused heart preparations of dogs.
Furukawa Y; Takayama S; Sawaki S; Inoue Y; Chiba S
J Pharmacol Exp Ther; 1993 May; 265(2):801-6. PubMed ID: 8496825
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the haemodynamic effects of the selective bradycardic agent UL-FS 49, with those of propranolol during treadmill exercise in dogs.
Krumpl G; Winkler M; Schneider W; Raberger G
Br J Pharmacol; 1988 May; 94(1):55-64. PubMed ID: 3401644
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".
Kobinger W; Lillie C
Eur J Pharmacol; 1984 Sep; 104(1-2):9-18. PubMed ID: 6499920
[TBL] [Abstract][Full Text] [Related]
8. Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: systemic and coronary hemodynamics with and without combined beta adrenergic blockade.
Warltier DC; Zyvoloski MG; Gross GJ; Brooks HL
J Pharmacol Exp Ther; 1984 Aug; 230(2):367-75. PubMed ID: 6146711
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of a potassium channel blocking drug, UK-68,798, and a specific bradycardic agent, UL-FS 49, on exercise-induced ischemia in the dog: significance of diastolic time on ischemic cardiac function.
Gout B; Jean J; Bril A
J Pharmacol Exp Ther; 1992 Sep; 262(3):987-94. PubMed ID: 1527735
[TBL] [Abstract][Full Text] [Related]
10. Regional redistribution of myocardial perfusion by UL-FS 49, a selective bradycardic agent.
O'Brien P; Drage D; Saeian K; Brooks HL; Warltier DC
Am Heart J; 1992 Mar; 123(3):566-74. PubMed ID: 1539507
[TBL] [Abstract][Full Text] [Related]
11. Prevention of tricyclic antidepressant-induced ventricular tachyarrhythmia by a specific bradycardic agent in a canine model.
Ansel GM; Meimer JP; Nelson SD
J Cardiovasc Pharmacol; 1994 Aug; 24(2):256-60. PubMed ID: 7526057
[TBL] [Abstract][Full Text] [Related]
12. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.
Pagel PS; Harkin CP; Hettrick DA; Warltier DC
J Pharmacol Exp Ther; 1995 Oct; 275(1):127-35. PubMed ID: 7562540
[TBL] [Abstract][Full Text] [Related]
13. Effects of the bradycardic agent UL-FS 49 on exercise-induced regional contractile dysfunction in dogs.
Raberger G; Krumpl G; Schneider W
Int J Cardiol; 1987 Mar; 14(3):343-54. PubMed ID: 3557712
[TBL] [Abstract][Full Text] [Related]
14. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity.
Millard RW; Grupp G; Grupp IL; DiSalvo J; DePover A; Schwartz A
Circ Res; 1983 Feb; 52(2 Pt 2):I29-39. PubMed ID: 6831652
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic antagonism of beta adrenergic blockade in dogs. II. Hemodynamic effects of simultaneous intravenous infusion of isoproterenol and dopamine during chronic propranolol administration.
Spotnitz HM; Avery GJ; Rose EA; Benvenisty AI; Malm JR; Hoffman BF
J Thorac Cardiovasc Surg; 1980 Jan; 79(1):103-8. PubMed ID: 6243164
[TBL] [Abstract][Full Text] [Related]
16. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs.
Simon L; Ghaleh B; Puybasset L; Giudicelli JF; Berdeaux A
J Pharmacol Exp Ther; 1995 Nov; 275(2):659-66. PubMed ID: 7473152
[TBL] [Abstract][Full Text] [Related]
17. Effect of a bradycardic agent on the isolated blood-perfused canine heart.
Schipke JD; Harasawa Y; Sugiura S; Alexander J; Burkhoff D
Cardiovasc Drugs Ther; 1991 Apr; 5(2):481-8. PubMed ID: 1854656
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one).
Dage RC; Roebel LE; Hsieh CP; Weiner DL; Woodward JK
J Cardiovasc Pharmacol; 1982; 4(3):500-8. PubMed ID: 6177949
[TBL] [Abstract][Full Text] [Related]
19. Actions of two new bradycardic agents, AQ-AH 208 and UL-FS 49, on ischemic myocardial perfusion and function.
Dämmgen JW; Lamping KA; Gross GJ
J Cardiovasc Pharmacol; 1985; 7(1):71-9. PubMed ID: 2580154
[TBL] [Abstract][Full Text] [Related]
20. Aortic peak flow velocity as an index of myocardial contractility in the conscious rat.
Dowell RT; Houdi AA
Methods Find Exp Clin Pharmacol; 1997 Oct; 19(8):533-9. PubMed ID: 9442476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
